Analyst consensus rating
Evolent Health Analyst Rating: Buy
EVH is rated Buy by 13 analysts with a $5.77 target. As of 2026-08-23.
Direct answer
Evolent Health's consensus rating is Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.77.
Forecast evidence checked August 23, 2026.
Get free Evolent Health email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.74
- Average price target
- $5.77
- High price target
- $8.00
- Low price target
- $3.00
- Low target gap
- -36.7%
- Target upside
- +21.7%
- High target gap
- +68.8%
- Target range width
- 105.5%
- Consensus rating
- Buy
- Analysts
- 13
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Evolent Health?
Evolent Health has a verified Buy consensus. The same dataset has an average price target of $5.77.
How far are Evolent Health's low and high targets from the recorded price?
The low target implies -36.7%, while the high target implies +68.8%.
How many analysts are included in Evolent Health's consensus?
The verified consensus includes 13 analysts.
How is Evolent Health's target upside or downside calculated?
The average target of $5.77 is divided by the recorded price of $4.74, then one is subtracted to produce +21.7%. This does not guarantee a future return.
When was Evolent Health's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.